Oct. 15, 2015 | Identifying a patient’s genetic mutation led University of Arkansas for Medical Sciences (UAMS) physician-researcher Ling Gao, M.D., Ph.D., to an existing drug that eliminated the patient’s stage IV Merkel-cell carcinoma. Gao’s findings, made in collaboration with two other UAMS researchers, were published today in The New England Journal of Medicine.

Gao is a recipient of the UAMS Translational Research Institute’s (TRI) KL2 Mentored Research Career Development Scholar Award, which provided two years of research funding and translational research training.

Metastatic Merkel-cell carcinoma is often fatal and there is no effective treatment. Gao’s 86-year-old female patient was diagnosed in 2013 with stage IIIB Merkel-cell carcinoma of the right temple. She had surgery and received radiation therapy in May 2013 and additional surgery in July 2014. In November 2014, doctors confirmed that the cancer had metastasized.

Gao, a dermatologist who treats Merkel-cell carcinoma patients from Arkansas and surrounding states, performed genetics tests on the tumor that revealed multiple mutations, including PI3Kδ.

Gao was aware that the drug idelalisib is a novel PI3K pathway inhibitor approved by the Food and Drug Administration (FDA) for treatment of B-cell lymphoma, a cancer of the blood. She was also aware of recent studies showing that disruption of the PI3Kδ mutation allows the body to mount an effective antitumor immune response.

On the basis of her laboratory work and knowledge of idelalisb, Gao began treatment of the patient with the drug on Feb. 6, 2015.

Three months after administering the idelalisib, there was no sign of the tumor in the patient’s liver, Gao said. Her findings were published in the Journal in a letter to the editor.

Based on what she’s learned, Gao said the case can be made for further study of PI3Kδ inhibitors like idelalisib in solid tumors, not just blood cancers.

“The efficacy of idelalisib in our patient provides initial clinical evidence that the targeting of PI3Kδ in Merkel-cell carcinoma is warranted,” Gao said in the letter, which  was also signed by UAMS’ Fade Mahmoud, M.D., and Mallory B. Shiver, M.D.

Gao also credits support she received from Peter Emanuel, M.D., director of the UAMS Winthrop P. Rockefeller Cancer Institute, and James Suen, M.D., chair of the Department of Otolaryngology-Head and Neck Surgery in the UAMS College of Medicine.

View the article and accompanying PET-CT findings here.

Gao’s research has been supported by the UAMS Translational Research Institute through the National Institutes of Health National Center for Advancing Translational Sciences, the Department of Dermatology in the UAMS College of Medicine, UAMS Winthrop P. Rockefeller Cancer Institute, and the Arkansas Biosciences Institute.

UAMS’ Aliza Brown, Ph.D., recently received a nearly $200,000 Genentech stroke research award after she incorporated ideas in her application from the first TRI Research Forum in June 2014.

The grant was one of only three community stroke pilots funded by Genentech in the United States. The study will enable Brown to determine paramedics’ recognition of stroke and whether stroke patients are being taken to stroke-ready hospitals.  In addition, she is developing an educational video for paramedics in partnership with the UAMS-led Arkansas SAVES (Stroke Assistance through Virtual Emergency Support) telestroke program and the Arkansas Department of Health’s Arkansas Stroke Registry.

Her hope is that the study will provide data to support state sanctioned stroke guidelines and practices for emergency medical services.

“The Department of Health is very interested in this project because this will help promote legislation for the stroke guidelines and to create a stroke dashboard to guide EMS agencies to the appropriate hospitals,” Brown said.

Brown, an assistant professor of radiology, joked that she was TRI’s first Research Forum “guinea pig.” The forums include established researchers and biostatisticians who provide feedback on investigators’ grant applications.

“The forum panel was excited about the application and said it was very translational,” Brown said. “They gave me some great advice. I learned a lot and I got a pretty good grant out of it.”

A key recommendation came from Jean McSweeney, Ph.D., R.N., professor and interim dean of the College of Nursing. “Dr. McSweeney suggested that the study include utilization of the Simulation Center and an educational intervention, so I did that,” Brown said.

Her study will validate the educational intervention – a training video – by measuring Pulaski County paramedics’ stroke recognition rates following training. Garland County EMS will serve as the control, where EMS workers will not receive the training video and whose stroke recognition rates will be followed concurrently.

“I hope that this study can provide data the state needs to make these stroke guidelines a reality,” Brown said.

To date, TRI has hosted nine Research Forums. To request a forum, email TRIservices@uams.edu.

Submitted on Sept. 25, TRI’s 1,263-page renewal application for a Clinical and Translational Science Award (CTSA) was made possible thanks to the dedication of faculty and staff across UAMS and its affiliated institutions, said TRI Director Laura James, M.D.

“Faculty reviewers and writers from across all colleges tackled this project in a spirit of teamwork that allowed us to develop the strongest possible application,” James said. “This was a cross-college, cross-department, cross-institution effort that involved basic scientists, clinical researchers, community engagement researchers, etc.”

Reviewers were Larry Cornett, Ph.D., Charlotte Hobbs, M.D., Ph.D., Donald Mock, M.D. Ph.D., Mike Owens, Ph.D., Paula Roberson, Ph.D., and Nancy Rusch, Ph.D. This group’s work included nine two-hour meetings. Other major contributors to the review group were DeAnn Hubberd and Peggy Brenner from the UAMS Office of Grants and Scientific Publications (OGSP).

Meanwhile, Mary Aitken, M.D., Pedro Delgado, M.D., and Rusch spent countless hours writing the application’s two training components, James said.

Other primary writers were Beatrice Boateng, Ph.D., Barry Brady, Mathias Brochhausen, Ph.D., Cornett, Geoff Curran, Ph.D., Gloria Richard-Davis, M.D., Ellen Fischer, Ph.D., Kristie Hadden, Ph.D., Hobbs, Laura Hutchins, M.D., Greg Kearns, Pharm.D., Ph.D., Brad Martin, Pharm.D., Ph.D., Pearl McElfish, Ph.D., Jean McSweeney, Ph.D., R.N., Mock, Pope L. Moseley, M.D., Alison Oliveto, Ph.D., Owens, Tamara Perry, M.D., Fred Prior, Ph.D., James Raczynski, Ph.D., Paula Roberson, Ph.D., Kate Stewart, M.D., M.P.H., Dennis Sullivan, M.D., Billy Thomas, M.D., and Pam Williams, Ph.D.

Valuable expertise was contributed by Hari Eswaran, Ph.D., as well as Barry Brady and Phaedra Yount from the Arkansas Children’s Research Institute (ACRI), and OGSP staff. TRI’s staff was critical to the process, James said, including Pamela Christie, Amy Jo Jenkins, Donna Mattingly, Anthony McGuire, and Laura Wilson, and many others who provided information for the grant.

If the application is successful, UAMS will receive about $24.4 million over five years. The CTSA Award is funded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS).

While the launch of the Integrated Clinical Enterprise is a focus point for UAMS this year, Dean Pope L. Moseley, M.D., assured faculty researchers at a Sept. 15 Town Hall meeting that a key objective of the service lines, and his top priority, is strengthening research and education programs.

“My goal is to make us better as an academic enterprise,” said Moseley, who is internationally known for his laboratory research in cellular adaptations to exercise and his expertise in biomedical informatics. He became dean in July after chairing the Department of Internal Medicine at the University of New Mexico School of Medicine for 14 years.

The forum, co-hosted by pediatrics Professor and Executive Associate Dean for Research Charlotte Hobbs, M.D., Ph.D., was well received by faculty members.

Stavros Manolagas, M.D., Ph.D., lauded Moseley’s arrival and strong support for the research enterprise as well as the commitment of UAMS leaders to support research with greater funding resources that are anticipated to be generated through the new clinical service lines.

“This is the most exciting news, I believe, at this institution in the 20 years that I have been here,” said Manolagas, a distinguished professor and director of the Division of Endocrinology and the internationally recognized UAMS Center for Osteoporosis and Metabolic Bone Diseases. “I want to wish you the best of luck,” he said, drawing a round of applause for Moseley.

Moseley noted that research and education are not self-supporting and that clinical revenue is by far the largest funding source for UAMS. “Research and education need fuel from the clinical engine,” he said.

An institution could hypothetically optimize the clinical delivery system at the expense of everything else, Moseley said.

“But that’s not who we are,” he said. “We didn’t come here to be a multi-specialty practice group. We came here to be a community of scholars. We are here to develop new knowledge and to train the next generation of scientists and clinicians.”

Moseley said he came to UAMS because he was impressed that an academic medical center had “the will” to completely change the clinical delivery model and system for managing the flow of its revenue in an effort to improve patient care while also generating new revenue for strategically planned research and education initiatives. “What we are all trying to do is to find that balance point,” he said.

Moseley outlined priorities for enhancing the research environment, including working with chairs to recruit outstanding researchers at all levels and in key areas that support research. He cited the recent recruitment of Fred Prior, Ph.D., from Washington University in St. Louis as the inaugural chair of the Department of Biomedical Informatics.

He said the college will work to support successful, established research programs and develop a systematic, central approach to bridge funding for successful investigators who experience lapses in extramural funding. Additionally, Moseley said he will work with research leaders to “lower the activation energy” required for successful research by addressing any barriers in areas such as human subject and animal care review.

Emphasizing the importance of chairs in determining how funds are allocated for research, he said a research-focused strategic retreat is being planned. Investigators can have input in the process through their chairs, he added.

An immediate priority is obtaining renewal of the Clinical and Translational Science Award (CTSA) from the National Institutes of Health National Center for Advancing Translational Sciences, which Moseley said is a “defining grant of an academic medical center.”

The UAMS Translational Research Institute (TRI), under the leadership of pediatrics Professor and TRI Director Laura James, M.D., has been preparing the CTSA renewal application to meet the Sept. 25 deadline. Moseley urged faculty members to support the final efforts that were underway.

Longer-range major institutional initiatives include building the biomedical informatics program under Prior’s leadership and preparing the Winthrop P. Rockefeller Cancer Institute’s application for National Cancer Institute designation in a couple of years, Moseley said.

The majority of the meeting was devoted to questions and comments about research priorities and needs. Recommendations from faculty members included developing an inpatient clinical research unit, improving access to research core services, and working more closely with the Central Arkansas Veterans Healthcare System (CAVHS) and leveraging VA grant opportunities for both basic and clinical researchers.

“Compared to other institutions that have VA facilities next door, we tend to underutilize their Career Development Program and the VA Merit Review Program,” said Curt Hagedorn, M.D., a Professor in the Division of Gastroenterology and Hepatology who serves as vice chair for VA Affairs in the Department of Internal Medicine and chief of Medicine at CAVHS.

Michael Jennings, Ph.D., professor and chair of the Department of Physiology and Biophysics and executive associate dean for Basic Sciences, said there is a misconception that VA awards aren’t available for basic scientists and lack of understanding about how to get into the VA system. “But this is something we can really take advantage of,” he said.

Moseley and faculty members spoke about the importance of growing the numbers of physician-scientists through recruitment, mentoring, training programs and other means.

John Arthur, M.D., Ph.D., director of the Division of Nephrology, used a football analogy in advocating for maximizing training grant opportunities, such as the NIH’s career development K awards.

“If you really want, over the long term, to have a team that can compete for the SEC championship year after year, you really have to grow it from the bottom up,” Arthur said.

The meeting opened with a presentation by Hobbs on new services for researchers, including improvements to the COM research website and the UAMS Grant Repository, which will provide junior faculty researchers with examples of submitted grant applications as a training resource to help them to improve their applications and chance of funding.

Hobbs showed a graph reflecting the downturn in NIH funding over the past five years. “We are really focused on turning that around,” she said.

Moseley also referred to the downturn in his remarks. “That is behind us,” he said. “It is our job to change course, and I am excited because we are going to do that.”

For more of Moseley’s thoughts on the importance of research and the academic mission, read his Executive Blog posts on the Inside UAMS intranet.

Learn More:

For information about eligibility and applying for VA grants, contact Sue Theus, Ph.D., deputy associate chief of staff/research, CAVHS, at (501) 257-4841 or Sue.theus@VA.gov.

Editor’s note: A version of this article also appears in the September COMmunication newsletter.

Discover Your Next Collaborator With UAMS Profiles

Finding collaborators doesn’t have to be a scavenger hunt. UAMS Profiles, a new online research networking tool, eliminates the mystery and the miles separating researchers from potential collaborators.

Created at Harvard University, Profiles was obtained and customized for use at UAMS by the Translational Research Institute (TRI), the Winthrop P. Rockefeller Cancer Institute and the Department of Biomedical Informatics. Through its service to researchers, UAMS Profiles delivers on a key team science objective of the NIH National Center for Advancing Translational Sciences (NCATS), which oversees 62 Clinical and Translational Science Award (CTSA) institutions across the United States, including TRI.

Profiles (TRI.uams.edu/Profiles) combines a key-word directory with illuminating interactive visualizations that show each faculty member’s collaborations or networks with other researchers, and it shows how those networks have evolved over time.

UAMS faculty information is currently shared within the UAMS network and may be viewed by Profiles members at the main UAMS campus, Arkansas Children’s Hospital and its Research Institute (ACRI), the UAMS Northwest Arkansas campus, and by faculty at the Central Arkansas Veterans Healthcare System. In 2016, UAMS Profiles will be linked nationally with other research institutions that use Profiles or similar networking programs.

Profiles accounts were automatically established for all UAMS faculty with information imported from UAMS FacFacts (Faculty Facts), TRACKS and PubMed. Each faculty member’s Profile Page includes biographical information, contact information and their researcher networks. A researcher’s network may be viewed on the website as:

You’ll want to check out the September TRIbune, which features UAMS Profiles, the exciting new platform for finding collaborators.  This issue also highlights a TRI-supported stroke researcher who received a Genentech grant, as well as TRI-cited publications by your colleagues.

Download PDF | View Newsletter Archive

Nancy Gray, Ph.D., has spent her first six months as UAMS BioVentures director focused on getting to know researchers and staff. She’s met with researchers interested in generating intellectual property, those who have generated intellectual property, and some who aren’t sure if they have.

“What I’ve found is that most researchers are so involved in the day-to-day of their programs that, generally, they aren’t thinking about whether they have invented something,” she said. “I believe there’s a lot more intellectual property here that we can capture.”

Gray’s outreach so far as generated an increasing number of researcher phone calls and emails, but she would like to receive more.

“If you have a question, call BioVentures,” she said. “Even if we don’t have an answer, we’ll find an answer. I would like to see BioVentures viewed as a resource as people think about their research work and what it might lead to in terms of commercialization.”

Gray has encountered a few misconceptions here, as well, such as that intellectual property relates only to patents, while in reality it may also involve copyright material and know-how.

BioVentures’ role includes finding licensees for a researcher’s intellectual property if the researcher chooses not to create a spin-off company. Gray has also focused on finding partners for UAMS researchers either through licensing of intellectual property or for sponsored research. While BioVentures does not manage sponsored research agreements, she said, there are opportunities for corporate sponsorships to develop early stage intellectual property through sponsored research or product licenses.

“If a researcher knows a certain company might be interested in their work, I would encourage them to reach out to BioVentures,” she said.

Another misconception Gray noted is that BioVentures offers a source of funding, as implied by its name. Although it doesn’t provide funding, Gray is in a position to help with that too.

“We’re not a venture group, per se, but we have the expertise here,” she said, noting BioVentures staff with business and financial backgrounds and her more than 30 years in biomedical industries, including medicinal chemistry research, management of pharmaceutical research and development, and business operations. Her experience and professional connections allow Gray to direct researchers to the right people.

“Each piece of intellectual property might have a different audience,” she said. “If it’s diagnostic based, the audience of companies would be much different than if it’s a therapeutic or vaccine or device.”

Gray’s experience also includes that of researcher and product developer. She is the inventor on 31 issued U.S. patents and the author of 23 publications. Her research on central nervous system diseases resulted in three products being accepted for clinical development in five years. She was also instrumental in the development of two marketed second generation antihistamines, Allegra and Xyxal.

UAMS Translational Research Institute (TRI) Director Laura James, M.D., noted that BioVentures is important to UAMS’ mission to improve its translation of new knowledge and discoveries into better health and health care. Gray participated in TRI’s strategic planning retreat just weeks after she arrived in March and is working with TRI on a program to reach a broader audience of researchers with an introduction to the concepts of intellectual property and the importance of protecting inventions.

Gray came to UAMS from the Southern Research Institute in Birmingham, Alabama, where she was vice president for corporate development. There, she led corporate development opportunities, including mergers and acquisitions, strategic alliances, joint ventures, minority investments, technology licenses and divestitures for the life sciences, engineering, and environment and energy business. Gray completed one joint venture agreement, 30 license agreements and 37 collaboration agreements.

Prior to her time at the Southern Research Institute, Gray worked in various executive roles at Beijing Med-Pharm Corporation, Vaxinnate Corportation and Elan Corporation.  She received her bachelor’s degree in chemistry from Bucknell University and her doctorate in medicinal chemistry from the University of Illinois.

Gray can be reached at nmgray@uams.edu or (501) 686-6696.